Radar Telegram alerts Open Radar

Aprea Therapeutics announces interim results from an ongoing first-in-human Phase 1 study of the WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR.

תרגם לעברית

Business Insider Markets · · Source

Aprea Therapeutics announces interim results from an ongoing first-in-human Phase 1 study of the WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR.

More on Radar

Want to see every report in real time?

Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.

Sign up free
Share on WhatsApp Get alerts on Telegram